Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC

Clinical trial NCT04665609 · UNKNOWN

Trial details

NCT number: NCT04665609
Sponsor: Chinese PLA General Hospital
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Thermal Ablation Anlotinib PDL-1

Start date: 2021-03-05
Primary completion: 2022-12-31
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.